Mesothelioma
📧 Sign up to get email alerts when something new happens for Mesothelioma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-08-18EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.
European Medicines Agency authorises Alimta (pemetrexed) for mesothelioma and non-small-cell lung carcinoma.
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Rapid Autopsy and Procurement of Cancer Tissue
The National Cancer Institute's trial NCT01851395 involving rapid autopsy and procurement of cancer tissue has completed, focusing on thymic…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
This prospective study evaluates high-resolution dual-energy CT imaging, noninvasive liquid biopsies, and minimally invasive surveillance fo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors [Phase 1]
This clinical trial update describes a Phase 1 study of PF-08046049/SGN-BB228 in advanced melanoma and other solid tumors, with the conditio…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma [Phase 2]
A Phase 2 trial of INQOVI (decitabine/cedazuridine) in patients with BAP1 tumor predisposition syndrome and subclinical, early-stage mesothe…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours [Phase 1]
Phase 1 trial update evaluating the combination of 177Lu-DOTA-TATE with Olaparib in somatostatin receptor-positive tumors has completed. The…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study of VET3-TGI in Patients With Solid Tumors [Phase 1]
Phase 1 clinical trial update for VET3-TGI in patients with solid tumors, currently recruiting across multiple cancer types.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]
Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors [Phase 1, Phase 2]
Clinical trial update for VT3989 in adults with metastatic solid tumors, including mesothelioma and non-small cell lung cancer, currently re…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [Phase 2]
Phase 2 trial assessing the imaging tracer 18F-FAPI-74 for cancer detection across multiple indications; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance [NA]
Massachusetts General Hospital reports an update on the Transitions Project, a study to support adults moving from cancer treatment to surve…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
An ongoing clinical trial is recruiting to study the frequency and clinical phenotype of BAP1 tumor predisposition syndrome and its associat…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Prospective Data Collection Initiative on Thoracic Malignancies
A prospective data collection initiative on thoracic malignancies sponsored by the Dutch Society of Physicians for Pulmonology and Tuberculo…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the safety and efficacy of a mesothelin-targeting logic-gated CAR T therapy in adults with solid tumors …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma [Phase 1]
Phase 1 clinical trial update for TNhYP218 anti-mesothelin CAR T cells in mesothelin-expressing solid tumors, including mesothelioma; recrui…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
This ClinicalTrials.gov entry describes a study by A2 Biotherapeutics evaluating HLA LOH analysis and apheresis for CAR-T cell manufacturing…
-
EMA approval · 2026-01-30EMA Authorised: Pemetrexed Accord (pemetrexed disodium hemipentahydrate) — Accord Healthcare S.L.U.
EMA authorised Pemetrexed Accord (pemetrexed disodium hemipentahydrate) for treatment of non-small cell lung cancer and mesothelioma; market…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A phase 1/2 study of TAK-500 with or without pembrolizumab in adults with select locally advanced or metastatic solid tumors; the trial was …
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Lead-212 PSV359 Therapy for Patients With Solid Tumors [Phase 1, Phase 2]
Perspective Therapeutics reports that Lead-212 PSV359 Therapy is being studied in Phase 1/2 trials for multiple solid tumors and is currentl…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Molecular Analysis of Thoracic Malignancies
This clinical trial update describes ongoing molecular analyses of thoracic malignancies, including thymic tumors and thoracic carcinomas, w…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
This study is recruiting long-term follow-up of mesothelioma patients and their family members who carry germline mutations in BAP1 and othe…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma [Phase 1, Phase 2]
Clinical trial update for VMD-928 as a monotherapy and in combination with pembrolizumab to treat TrkA overexpression-driven solid tumors or…